特发性肺纤维化患者的 FVC 变异性和 6 分钟步行试验预测进一步变化的作用。
FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change.
机构信息
Inova Fairfax Hospital, Falls Church, VA, USA
Genentech, Inc., South San Francisco, CA, USA.
出版信息
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.02151-2019. Print 2020 May.
Abstract
相似文献
1
FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change.特发性肺纤维化患者的 FVC 变异性和 6 分钟步行试验预测进一步变化的作用。
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.02151-2019. Print 2020 May.
2
Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.特发性肺纤维化患者的预后和体力活动的纵向变化。
BMC Pulm Med. 2017 Jul 25;17(1):104. doi: 10.1186/s12890-017-0444-0.
3
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.特发性肺纤维化合并轻度生理损害的疾病进展：来自澳大利亚特发性肺纤维化登记处的分析。
BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.
4
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.重组人 Pentraxin 2 与安慰剂对特发性肺纤维化患者用力肺活量变化的影响：一项随机临床试验。
JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.
5
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.在接受吡非尼酮治疗的特发性肺纤维化患者中，高分辨率计算机断层扫描结果的恶化预示着在用力肺活量首次下降后疾病的进展。
Respir Investig. 2020 May;58(3):185-189. doi: 10.1016/j.resinv.2019.12.007. Epub 2020 Feb 23.
6
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.接受吡非尼酮治疗的特发性肺纤维化患者的抗酸治疗与疾病进展
Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.
7
Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.特发性肺纤维化疾病严重度范围的多维评估。
Lung. 2018 Dec;196(6):707-713. doi: 10.1007/s00408-018-0152-4. Epub 2018 Aug 27.
8
Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?评估吡非尼酮对特发性肺纤维化的治疗反应：我们能否比仅使用用力肺活量做得更好？
Lung. 2017 Feb;195(1):101-105. doi: 10.1007/s00408-016-9963-3. Epub 2016 Nov 17.
9
Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者的移动健康监测
Ann Am Thorac Soc. 2019 Oct;16(10):1327-1329. doi: 10.1513/AnnalsATS.201904-335RL.
10
The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis.特发性肺纤维化中 6 分钟步行试验的价值和应用。
Ann Am Thorac Soc. 2018 Jan;15(1):3-10. doi: 10.1513/AnnalsATS.201703-244FR.
引用本文的文献
1
Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis.与年龄相关的疾病作为抗衰老疗法的试验平台：以特发性肺纤维化为例
Aging (Albany NY). 2025 Aug 16;17(8):1911-1928. doi: 10.18632/aging.206301.
2
Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot study.尼达尼布治疗进行性纤维化间质性肺疾病患者的循环生物标志物：一项试点研究。
Sci Rep. 2025 Jul 25;15(1):27115. doi: 10.1038/s41598-025-12952-1.
3
Computer-Aided Evaluation of Interstitial Lung Diseases.间质性肺疾病的计算机辅助评估
Diagnostics (Basel). 2025 Apr 7;15(7):943. doi: 10.3390/diagnostics15070943.
4
Mortality-related risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.特发性肺纤维化的死亡相关危险因素：一项系统评价与荟萃分析
J Thorac Dis. 2024 Dec 31;16(12):8338-8349. doi: 10.21037/jtd-23-1908. Epub 2024 Dec 20.
5
Correlation between CT-based phenotypes and serum biomarker in interstitial lung diseases.基于 CT 的表型与间质性肺疾病血清生物标志物的相关性。
BMC Pulm Med. 2024 Oct 19;24(1):523. doi: 10.1186/s12890-024-03344-8.
6
Repetitive invasive lung function maneuvers do not accentuate experimental fibrosis in mice.重复的有创性肺功能操作不会加重实验性小鼠的纤维化。
Sci Rep. 2024 Jun 14;14(1):13774. doi: 10.1038/s41598-024-64548-w.
7
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.贝索特格拉斯特治疗特发性肺纤维化患者：INTEGRIS-IPF 临床试验。
Am J Respir Crit Care Med. 2024 Aug 15;210(4):424-434. doi: 10.1164/rccm.202403-0636OC.
8
Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis.利用博来霉素模型的转化能力：为特发性肺纤维化药物研发提供指导的新见解。
Front Pharmacol. 2023 Nov 30;14:1303646. doi: 10.3389/fphar.2023.1303646. eCollection 2023.
9
Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.吡非尼酮和尼达尼布的比较：特发性肺纤维化清除研究的事后分析。
Chest. 2024 May;165(5):1163-1173. doi: 10.1016/j.chest.2023.11.035. Epub 2023 Nov 27.
10
Precision medicine advances in idiopathic pulmonary fibrosis.特发性肺纤维化的精准医学进展。
EBioMedicine. 2023 Sep;95:104766. doi: 10.1016/j.ebiom.2023.104766. Epub 2023 Aug 23.
本文引用的文献
1
Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.肺功能测定标准化 2019 修订版。美国胸科学会和欧洲呼吸学会官方技术声明。
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.
2
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者用力肺活量急性加重和下降与死亡率升高相关。
Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.
3
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者用力肺活量出现具有临床意义的下降后继续使用吡非尼酮治疗的效果：来自三项3期试验的数据分析
Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.
4
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.特发性肺纤维化患者住院和用力肺活量终点与生存的相关性：三项临床试验汇总队列分析。
Lancet Respir Med. 2015 May;3(5):388-96. doi: 10.1016/S2213-2600(15)00093-4. Epub 2015 Apr 15.
5
Combination therapy: the future of management for idiopathic pulmonary fibrosis?联合治疗：特发性肺纤维化治疗的未来？
Lancet Respir Med. 2014 Nov;2(11):933-942. doi: 10.1016/S2213-2600(14)70232-2. Epub 2014 Nov 3.
6
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化患者的 3 期临床试验。
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
7
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
8
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.6 分钟步行距离是特发性肺纤维化患者死亡率的独立预测因子。
Eur Respir J. 2014 May;43(5):1421-9. doi: 10.1183/09031936.00131813. Epub 2013 Dec 5.
9
Predicting pulmonary fibrosis disease course from past trends in pulmonary function.从过去的肺功能趋势预测肺纤维化疾病进程。
Chest. 2014 Mar 1;145(3):579-585. doi: 10.1378/chest.13-0844.
10
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.吡非尼酮治疗特发性肺纤维化（CAPACITY）患者的两项随机试验。
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.
Zotero 插件